Objective
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.
Fields of science
Call for proposal
H2020-JTI-IMI2-2019-18-two-stage
See other projects for this call
Funding Scheme
IMI2-RIA - Research and Innovation actionCoordinator
97080 Wurzburg
Germany
Participants (26)
20132 Milano
WC1E 6BT London
1105AZ Amsterdam
92513 Boulogne Billancourt
75654 Paris
63225 Langen
00165 Roma
1090 Wien
08036 Barcelona
80686 Munchen
80333 Muenchen
97076 Wurzburg
1000 Bruxelles
3631 Maasmechelen
31080 Pamplona
3062 PA Rotterdam
51429 Bergisch Gladbach
08041 Barcelona
4362 Esch-sur-alzette
51373 Leverkusen
2340 Beerse
92284 Courbevoie
8152 Glattpark
2514 AA Den Haag
2333 BE Leiden
2017 Boudry
